Oncobiologics (NASDAQ:OTLK – Get Free Report) and Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Profitability
This table compares Oncobiologics and Arcturus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncobiologics | N/A | N/A | -254.82% |
| Arcturus Therapeutics | -317.62% | -46.54% | -36.46% |
Analyst Ratings
This is a summary of current recommendations and price targets for Oncobiologics and Arcturus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncobiologics | 1 | 2 | 2 | 0 | 2.20 |
| Arcturus Therapeutics | 1 | 1 | 6 | 2 | 2.90 |
Oncobiologics currently has a consensus target price of $5.20, suggesting a potential upside of 901.35%. Arcturus Therapeutics has a consensus target price of $22.29, suggesting a potential upside of 126.48%. Given Oncobiologics’ higher probable upside, equities research analysts plainly believe Oncobiologics is more favorable than Arcturus Therapeutics.
Insider and Institutional Ownership
11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Oncobiologics and Arcturus Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncobiologics | $1.35 million | 93.65 | -$62.42 million | ($0.77) | -0.67 |
| Arcturus Therapeutics | $82.03 million | 3.41 | -$65.78 million | ($3.31) | -2.97 |
Oncobiologics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500.
Summary
Arcturus Therapeutics beats Oncobiologics on 8 of the 15 factors compared between the two stocks.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
